# Best Peptides for Nerve Injury & Neuropathy: Clinical Evidence (2026)

> A clinical, evidence-graded ranking of the peptides studied for nerve injury and neuropathy — ARA-290, Cerebrolysin, BPC-157 and Cortagen — separating genuine human RCT data from animal-only signal.

*Published 2026-07-01 · Updated 2026-07-01 · By Marcus Feld, PharmD, BCPS*

The short answer
Nerve repair is one of the few areas in the peptide space with **genuine randomized human evidence** — but only for one compound. **ARA-290 (cibinetide)** has double-blind, placebo-controlled human trials showing objective small-nerve-fiber regeneration (**Grade B**).[1](https://peptidevox.com/#r1) **Cerebrolysin** has a single small peripheral-neuropathy RCT (Grade B) atop a large, contested central-nerve-injury literature.[6](https://peptidevox.com/#r6) **BPC-157** and **Cortagen** have consistent-to-single-lab animal data but **no human nerve trials** (Grade C).[11](https://peptidevox.com/#r11)[17](https://peptidevox.com/#r17) No peptide is FDA-approved for neuropathy.

Search "peptides for nerve repair" and the marketing collapses BPC-157, ARA-290, Cerebrolysin and Cortagen into a single promise: regrow damaged nerves. The evidence does not. This ranking separates the one compound with blinded human regeneration data from the ones resting on animal models or a single research network — and grades each honestly.

*This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a prescription or protocol to follow, and not a sourcing or buying guide. None of these peptides is an FDA-approved treatment for nerve injury or neuropathy; most are sold only as "research chemicals not for human use," and several are prohibited in sport. Dosing figures are reported strictly as they appear in the published literature and registered trials — never as recommendations. Consult a qualified, licensed clinician before acting on any health information.*

## How could peptides help injured nerves at all?

Neuropathy and nerve injury share a final common biology: axonal damage, loss of myelin and small or large nerve fibers, mitochondrial and oxidative stress, micro-vascular insufficiency of the vasa nervorum, and a maladaptive neuro-inflammatory response. The peptides studied for nerve repair act on subsets of this cascade. ARA-290 selectively activates the innate repair receptor — a heterocomplex of the EPO-receptor subunit with the β-common receptor (CD131) that is locally upregulated under injury, hypoxia and inflammation — triggering anti-apoptotic and anti-inflammatory signaling while damping spinal microglial activation, without the red-cell-raising effect of EPO itself.[2](https://peptidevox.com/#r2)[5](https://peptidevox.com/#r5) This is the mechanism most directly tied to a human nerve-regeneration readout.

Cerebrolysin, a porcine-brain-derived peptide and amino-acid mixture, is claimed to mimic endogenous BDNF, NGF, GDNF and CNTF activity, though its specific active fraction remains undefined.[6](https://peptidevox.com/#r6) BPC-157 acts in animals through the nitric-oxide system and pro-angiogenic VEGFR2–Akt–eNOS signaling, restoring perfusion and supporting axonal regrowth and remyelination.[13](https://peptidevox.com/#r13) Cortagen, a Khavinson-program tetrapeptide, is hypothesized to enter the nucleus and modulate tissue-specific transcription.[17](https://peptidevox.com/#r17) A plausible mechanism, however, is not efficacy — only ARA-290 has translated mechanism into a blinded human nerve-regeneration endpoint.

## Which peptide has real human nerve-regeneration data?

Exactly one: ARA-290. In the pivotal Phase 2b dose-ranging trial in sarcoidosis-associated small-fiber neuropathy (n=64; 1, 4 or 8 mg subcutaneous daily for 28 days), the 4 mg dose significantly increased corneal nerve fiber area (placebo-corrected +697 µm²; 95% CI 159–1236; P=0.012 — roughly a 23% increase) and increased skin GAP-43+ regenerating intraepidermal nerve fibers (P=0.035), with the two regeneration markers correlating with each other and with the 6-minute walk test.[1](https://peptidevox.com/#r1) That trial is registered and reported at [ClinicalTrials.gov (NCT02039687)](https://clinicaltrials.gov/study/NCT02039687), where the completed protocol and results can be inspected directly.[4](https://peptidevox.com/#r4) An earlier pilot RCT (n=22) improved the Small Fiber Neuropathy Screening List score versus placebo.[3](https://peptidevox.com/#r3) In type 2 diabetic neuropathy (n=48; 4 mg SC daily for 28 days), ARA-290 improved neuropathic symptoms and, in the low-baseline subgroup, increased corneal nerve-fiber density — all without raising hemoglobin or hematocrit.[2](https://peptidevox.com/#r2)

The honest limits matter. All of this is Phase 2, from a single Leiden/Araim research network, never advanced to Phase 3 or approval, and the celebrated pain relief was inconsistently superior to placebo even in the positive trials.[1](https://peptidevox.com/#r1) Animal data extend to a rat spared-nerve-injury model, but that does not upgrade the human grade.[5](https://peptidevox.com/#r5) PeptideVox grades ARA-290 **B** for small-fiber neuropathy.

## How do the four peptides rank on evidence?

  Peptides for nerve injury & neuropathy — evidence at a glance

    PeptideBest evidenceEndpointGrade

    ARA-290 (cibinetide)Double-blind Phase 2 RCTs (sarcoidosis + type 2 diabetes)Objective nerve-fiber regenerationB
    CerebrolysinOne small peripheral-neuropathy RCT; large contested CNS RCTsPain (VAS) symptom scoreB (peripheral)
    BPC-157Consistent rat sciatic-nerve & spinal-cord-injury modelsFunction, EMG, histology (animal)C
    CortagenSingle-lab rat sciatic-nerve studyGrowth rate, conduction velocity (animal)C

Cerebrolysin ranks second on the strength of its human footprint, but with a crucial caveat: the large trials are for central nerve injury (stroke, TBI), while its peripheral-neuropathy human evidence is a single small German double-blind trial (about 25 patients) showing a roughly 34% VAS pain reduction over a 10-day course versus a non-significant placebo change.[9](https://peptidevox.com/#r9) That is a symptom endpoint, not nerve regeneration. Meanwhile the independent 2023 Cochrane review of acute ischemic stroke (7 RCTs, 1,773 patients) found little to no difference in death or death-or-dependence and a possible increase in non-fatal serious adverse events (RR 2.39, 95% CI 1.10–5.23).[6](https://peptidevox.com/#r6) The manufacturer-associated positive trials (CARS, CAPTAIN) should not be read as peripheral-nerve evidence.[7](https://peptidevox.com/#r7)[8](https://peptidevox.com/#r8)

## Why are BPC-157 and Cortagen graded down despite strong animal data?

Because a rat is not a human, and neither compound has a completed human nerve trial. BPC-157 has the deepest, most internally consistent preclinical nerve dataset: in rat traumatic-nerve-injury models it improved walking recovery (Sciatic Functional Index), EMG motor action potentials, and histomorphometry, and in a rat spinal-cord-injury model a single dose produced progressive motor recovery and reduced axonal and motoneuron loss out to 360 days.[11](https://peptidevox.com/#r11)[12](https://peptidevox.com/#r12) Yet total published human exposure is a couple dozen subjects in uncontrolled safety pilots (including an n=2 IV study), with no validated pharmacokinetics.[15](https://peptidevox.com/#r15)[14](https://peptidevox.com/#r14) The only registered Phase 2 RCT is for hamstring strain, not nerve injury.[16](https://peptidevox.com/#r16) Grade **C**.

Cortagen is graded down further for lack of replication. Its concrete signal — a roughly 27% faster fiber growth rate and 40% higher conduction velocity in transected rat sciatic nerve at 10 µg/kg IM for 10 days — comes from a single Russian research network, unreplicated externally.[17](https://peptidevox.com/#r17) Its central-neuroprotection and gene-expression data come from the same lineage.[18](https://peptidevox.com/#r18)[19](https://peptidevox.com/#r19) The frequently repeated claim that Cortagen restores human peripheral nerve traces to review or vendor assertions, not a controlled trial — Grade **D** when applied to humans, with the animal data graded **C**.[20](https://peptidevox.com/#r20)

## What is the FDA, safety and WADA status in 2026?

None of these peptides is FDA-approved for nerve injury or neuropathy. ARA-290 holds Orphan Drug and Fast Track designation for sarcoidosis neuropathic pain — designation, not approval — with its developer effectively dormant.[25](https://peptidevox.com/#r25) Cerebrolysin has no U.S. NDA and no 503A/503B compounding pathway; it is approved in 45+ other countries under varying standards.[6](https://peptidevox.com/#r6) BPC-157 was placed on the 503A Category 2 bulk-substances list in September 2023, then removed on April 15, 2026 (a nomination withdrawal, not a safety clearance), with PCAC review slated for July 23, 2026 — removal does not authorize compounding.[23](https://peptidevox.com/#r23) Cortagen is not on any FDA bulk list and is sold only as a research chemical.[24](https://peptidevox.com/#r24)

On safety, all four are parenteral peptides with limited or absent long-term human data for nerve indications; pro-angiogenic or regenerative mechanisms raise theoretical caution in active or prior malignancy, and Cerebrolysin is additionally contraindicated in epilepsy.[10](https://peptidevox.com/#r10) For anything sold as a research chemical, product-quality risk — contamination, endotoxin, mislabeled dose — is frequently the largest practical hazard.[26](https://peptidevox.com/#r26) For athletes: ARA-290 is prohibited at all times under WADA S2.1, and BPC-157 is prohibited at all times under S0 with documented sanctions; Cerebrolysin and Cortagen plausibly fall under the S0 catch-all and should be treated as high-risk.[21](https://peptidevox.com/#r21)[22](https://peptidevox.com/#r22)

**Bottom line.** There is no FDA-approved peptide disease-modifying therapy for any neuropathy as of 2026, and nothing here replaces guideline care — glycemic control in diabetes plus agents such as duloxetine, pregabalin and gabapentin. From a functional, root-cause view, the most defensible nerve-supportive strategy remains addressing the driver of the damage while recognizing that these peptides range from a modest, real early human signal (ARA-290) down to single-lab animal data (Cortagen). Regulatory facts here are current as of June 2026; the July 23, 2026 PCAC outcome was pending at the time of writing and should be re-verified after that date.

---
Source: https://peptidevox.com/injuries-and-orthopedics/peptides-for-nerve-injury-neuropathy
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt